Abstract
Sulforaphane (SFN) is a potent inducer of detoxication enzymes such as NAD(P)H:quinone oxidoreductase (NQO1) and glutathione S-transferases (GST) via the Kelch-like ECH-associated protein 1 (Keap1) -NF-E2-related factor 2 (Nrf2) signaling pathway. NQO1 reduces the carcinogenic estrogen metabolite, catechol estrogen-3,4-quinone, while GSTs detoxify it through conjugation with glutathione. These 3,4-quinones can react with DNA to form depurinating DNA adducts. Thus, SFN may alter estrogen metabolism and thus protect against estrogen-mediated DNA damage and carcinogenesis. Human breast epithelial MCF10A cells were treated with either vehicle or SFN and either estradiol (E 2 ) or its metabolite 4-OHE 2 . 4-Hydroxy derived estrogen metabolites and depurinating DNA adducts formed from E 2 and its interconvertable metabolite estrone (E 1 ) were analyzed by mass spectrometry. Levels of the depurinated adducts, 4-OHE 1/2 -1-N3Adenine and 4-OHE 1/2 -1-N7Guanine, were reduced by 60% in SFN treated cells, while levels of 4-OCH 3 E 1/2 and 4-OHE 1/2 -glutathione conjugates increased. To constitutively enhance the expression of Nrf2-regulated genes, cells were treated with either scrambled or siKEAP1 RNA. Following E 2 or 4-OHE 2 treatments, levels of the adenine and guanine adducts dropped 60% -70% in siKEAP1 treated cells while 4-OHE 1/2 -glutathione conjugates increased. However, 4-OCH 3 E 1/2 decreased 50% after siKEAP1 treatment. Thus, treatment with SFN or siKEAP1 has similar effects on reduction of depurinating estrogen-DNA adduct levels following estrogen challenge.
However, these pharmacologic and genetic approaches have different effects on estrogen metabolism to O-methyl and glutathione conjugates. Activation of the Nrf2 pathway, especially elevated NQO1, may account for some but not all of the protective effects of SFN against estrogen-mediated DNA damage. [1] . Studies in experimental animal models demonstrate that estradiol (E 2 ) and estrone (E 1 ) are carcinogenic [2] and studies in cultured human cells [3; 4] provide a mechanistic basis for this effect. Observational studies and clinical trials consistently support the contention that sustained exposure to endogenous estrogens is associated with the development of sporadic breast cancer. Two complementary pathways are likely required for estrogen carcinogenicity [2] . One involves signaling through the estrogen receptor (ER) leading to altered gene expression and increased proliferation accompanied by spontaneous mutations [5] . The other pathway, outlined in Figure 1 , involves the oxidative metabolism of E 1 or E 2 to catechol estrogens and then reactive quinone metabolites. These metabolites can then directly and/or indirectly cause DNA damage and mutations responsible for the initiation and progression to breast cancer.
Metabolism of estrogens is characterized by a balanced set of activating and deactivating pathways. Aromatization of androstenedione and testosterone by aromatase (CYP19) yields E 1 and E 2 , respectively. E 1 and E 2 are interconverted by 17β-hydroxysteroid dehydrogenase, and they are metabolized at the 2-or 4-position to form 2-OHE 1/2 or 4-OHE 1/2 , respectively. CYP1A1 preferentially hydroxylates E 1 and E 2 at C-2, whereas CYP1B1 almost exclusively catalyzes the formation of 4-OHE 1/2 [6] . The most common pathway of conjugation of estrogens in extrahepatic tissues is O-methylation, catalyzed by catechol-O-methyltransferase (COMT). If the activity of COMT is low, CYP or peroxidases can catalyze competitive oxidation of the catechol estrogens to E 1/2 -2,3-quinones and E 1/2 -3,4-quinones. Higher levels of depurinating DNA adducts are formed by E 1/2 -3,4-quinones compared to E 1/2 -2,3-quinones due to different mechanisms of adduction [7] . The E 1/2 -3,4-quinones react via a 1,4-Michael addition, whereas the E 1/2 -2,3-quinones rearrange to p-quinone methides, which react via a 1,6-Michael addition [8] . These adducts generate apurinic sites that can be converted into mutations by errorprone repair, which in turn may initiate breast carcinogenesis [9] . Consistent with these actions, E 1/2 -3,4-quinone produced A-T to G-C mutations in the DNA of the mammary gland of ACI rats [10] . While the estrogen oxidation pathway is detrimental to the integrity of DNA, several protective pathways in cells control the homeostasis of estrogen metabolism to avoid DNA damage. Catechol estrogens can be detoxified by COMT, and the E 1/2 -3, 4-quinones by conjugation with glutathione or by reduction back to catechol estrogens, catalyzed by NAD(P)H:quinone oxidoreductase 1 (NQO1) [8] (Fig.1) . Diminished expression of detoxication enzymes and/or upregulation of enzymes of the oxidation pathway can disrupt this homeostasis. For example, higher expression of CYP19 and CYP1B1, or lower expression of COMT and NQO1, in breast tissues is associated with elevated risk of breast cancer [11] . Gaikwad et al. [12; 13] and Pruthi et al. [14] have reported that there is a significantly higher ratio of depurinating DNA adducts to other estrogen metabolites when comparing women at high risk for breast cancer or diagnosed with the disease to controls, indicating that formation of depurinating estrogen-DNA adducts likely plays key roles in breast cancer development.
Sulforaphane (SFN) is an isothiocyanate found in cruciferous vegetables with particularly high levels in 3-day old broccoli sprouts (15) . It is converted by hydrolysis of the glucosinolate, glucoraphanin, by the enzyme, myrosinase, found in plants or by β-thioglucosidases found in the gut microflora. SFN is an attractive chemopreventive agent since it is safe and can be distributed widely as broccoli sprout preparations. Moreover, SFN and broccoli sprout preparations are effective chemopreventive agents in rodent models of mammary carcinogenesis (15; 16) and initial pharmacokinetic studies indicate that pharmacologically relevant concentrations of sulforaphane metabolites can be detected in the mammary epithelium of women consuming broccoli sprout derived beverages (17) . An important, but far from unilateral, mechanism of action for SFN is the induction of carcinogen detoxication enzymes such as NQO1 and glutathione Stransferases (GSTs). SFN is an activator of the antioxidant response element -Keap1-Nrf2 signaling pathway regulating the expression of these and many other genes [18] .
Under normal cellular conditions, Nrf2 binds to Keap1 in the cytoplasm, resulting in ubiquitination of Nrf2 and its subsequent proteasomal degradation [19] . SFN can modify cysteine 151 in Keap1 to disrupt the association of Cul3 ubiquitin ligase with Keap1, allowing Nrf2 to escape degradation. Thus, Nrf2 is stabilized and translocates into the nucleus to induce the transcription of its target genes such as NQO1 and GST [3, 20] .
Using transcriptomic and proteomic profiling, we have shown previously, that SFN induces Nrf2-regulated genes in ERα negative, non-tumorigenic human breast epithelial (20) , and primary cultures of human mammary epithelial cells (21) . Interesting, these profiles were similar to those provoked by treatment of the MCF-10A cells with siRNA vectors for KEAP1 knockdown (20) . In the present study, we have evaluated the efficacy of SFN to alter estrogen metabolism away from the formation of DNA adducts through induction of detoxication genes and to determine the extent to which such protection can be mimicked by genetic amplification of the Nrf2 signaling pathway through KEAP1 knockdown. Standards of the glutathione conjugates of 4-OHE 2 and the depurinating DNA adducts were synthesized by published procedures [7, [22] [23] [24] . A mixed standard solution of 10 µg/mL was obtained by mixing 10 µL of individual stock solutions (1 mg/mL) and diluting to 1 mL with methanol/water 50:50 with 0.1% formic acid. Serial dilutions of this solution were used as standards for the preparation of calibration curves. Stock standard solutions and mixed standard solutions were stored at −80 ºC. Sulforaphane (1-isothiocyanato-4-(methylsulfinyl)-butane) was purchased from LKT Laboratories (St.
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Paul, MN). The glutathione (reduced) quantification kit was purchased from Dojindo Molecular Technologies (Rockville, MD). All other chemicals were the highest quality obtainable commercially.
Cell lines and cell culture
MCF-10A cells were obtained from the American Type Culture Collection and cultured in estrogen-free medium at 37ºC in a humidified incubator containing 5% CO 2 .
Cell culture medium was prepared by a phenol red-free mixture of Dulbecco's modified Eagle's media and Ham's nutrient mixture F-12 media (Mediatech, Manassas, VA) containing 20 ng/mL epidermal growth factor, 10 µg/mL insulin, 0.5 µg/mL hydrocortisone, 100 ng/mL cholera toxin and 5% charcoal-stripped FBS (Invitrogen, Inc.) (25) .
For SFN treatment, cells were seeded in 10-cm dishes (1-2×10 6 cells/10 ml media/dish) overnight and then treated with either vehicle or SFN for 24 hr. After immediately or frozen at -80ºC prior to assay for estrogen metabolites and depurinating DNA adducts. Cells were harvested for RNA, protein and activity assays.
qRT-PCR
Total RNA was isolated using the Qiagen RNeasy Mini Kit (Qiagen, Germantown, MD) or 5 PRIME PerfectPure RNA Cell & Tissue Kit (5PRIME, Gaithersburg,MD), from which cDNA was synthesized using the qScript TM cDNA synthesis kit (Quanta BioSciences, Gaithersburg, MD). PCR was carried out in a 20 µl volume including each target primer, cDNA and iQ™ SYBR ® Green Supermix (Bio-Rad, Hercules, CA) and run in a Bio-Rad Thermal Cycler (Bio-Rad, Hamburg, Germany).
Fold-change values were determined using the 2 -∆∆Ct relative quantification method [26] .
The amplified products were electrophoresed on agarose gel and stained with ethidium bromide.
PCR primers were as follows: forward 5′-TGACAATGAGGTTTCTTCGG-3′ and reverse 5′-TCTGTCAGTTTGGCTTCTGG-3′ for human Nrf2; forward 5′- ACGTCCTTGGAGGCTATGAT-3′ and reverse 5′-TCTGCTGGTCAATCTGCTTC -3 ′ for human KEAP1; forward 5′-CGCTTCTCTTGGAGGAATGT -3′ and reverse 5′ -TCCACCACCTCCCTGTATTC -3′ for human COMT; forward 5′-TTCCGGAGTAAGAAGGCAGT -3′ and reverse 5′-GGAGTGTGCCCAATGCTAT -3 ′ for human NQO1; forward 5′-TAAAGGAGAGAGCCCTGATTG -3′ and reverse 5 ′-TTCAAAGGCAGGGAAGTAGC -3′ for human GSTA1; forward 5′-GGACTCATGACCACAGTCCA -3′ and reverse 5′-CTGCTTCACCACCTTCTTGA -3 ′ for GAPDH.
Western blots
After treatment, cells were harvested and then lysed in RIPA buffer with protease inhibitor (Roche Diagnostics GmbH, Mannheim, Germany) and unlysed cellular debris removed by centrifugation. Protein concentrations were determined by using the BCA protein assay kit (Pierce Biotechnology, Rockford, IL). Western blot procedures followed the ABC protocol. Samples were electrophoresed on SDS-PAGE and transferred to polyvinylidene difluoride membranes. The membranes were blocked in TBS-0.05% Tween 20 with 5% non-fat milk, incubated with primary antibodies, and incubated with a peroxidase-conjugated secondary antibody after extensive washing. Dilutions of primary anti-KEAP1, Nrf2, NQO1 (Santa Cruz), CYP1B1 (Genetest, Bedford, A), COMT, GSTA1 and β-actin (Sigma) antibodies, were made in blocking solution (5% non-fat dry milk in TBS). The blots were incubated with Western Lightning ® Plus-ECL solution (PerkinElmer, Waltham, MA) and visualized with X-ray film. Intensities of the bands were quantified by Bio-Rad Quantity One ® software (Bio-Rad, Hercules, CA). The densitometry ratios for treated samples compared to controls were determined for three biological replicates and normalization was to β-actin.
NQO1 activity
MCF-10A cells were washed three times with 0.25 M sucrose/10 mM potassium phosphate (pH 7.2),collected from the plates by scraping, frozen in liquid nitrogen, and stored at -80°C for assay as described previously (27) .
UPLC-MS/MS analysis of estrogen metabolites and depurinating DNA adducts
Extraction of estrogen metabolites and depurinating DNA adducts from cell culture media was modified from previously described procedures (12) . After adjusting the pH to 7, cell culture media (10 mL/sample) was loaded onto phenyl cartridges (Agilent Technologies) that were preconditioned with methanol and water. Extracts were Table 1 . The coefficient of variance for all analytes was < 4%.The
Xcalibur software (Thermo) was used to process and quantify the acquired data of estrogen metabolites.
Statistics
The data are presented as means ± standard error of at least three independent experiments. Comparisons between two groups were analyzed using the Student t-test, and significance was established at p < 0.05 using Prizm 5 software.
Results
Modulation of transcripts, protein expression and activity of estrogen metabolism enzymes by SFN treatment or KEAP1 knockdown
Treatment of MCF-10A cells with SFN led to induction of GSTA1 and NQO1 transcripts but no changes in expression levels of two other genes known to influence E 2 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 9 metabolism, namely CYP1B1 and COMT, were observed (Fig. 3A) . These inductions exhibited a dose-response, with minimal induction observed with 3 µM, moderate with 7 µM and near maximal with 10 µM SFN (data not shown). As expected, there were also no changes in the transcript levels of KEAP1 or NRF2. SFN treatment significantly elevated NQO1 protein level 3.0 fold (p<0.01; SFN treatment versus vehicle, Fig. 3B) and its specific activity 2.7-fold (p<0.01; SFN treatment versus vehicle, Fig. 3C ).
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Although no change of COMT mRNA level was detected, a significant 2.4-fold increase in COMT protein (p<0.05; SFN treatment versus vehicle, Fig. 3B ) was observed.
CYP1B1 protein was significantly decreased by 50% with SFN treatment (Fig.3B) (p<0.05; SFN treatment versus vehicle). Thus, it appears SFN influences the expression of E 2 metabolizing enzymes through both transcriptional and post-transcriptional mechanisms. As expected, SFN and siKEAP1 also lead to increases in intracellular concentrations of reduced glutathione in MCF-10A cells (1.48 and 1.71-fold, respectively).
Since SFN is a well characterized activator of Nrf2 signaling in MCF-10A and other mammary cells (20, 21) , the influence of siKEAP1 knockdown, and hence genetic activation of the pathway was evaluated. Shown in Fig. 4, transcript (Fig. 4A) , protein ( Fig. 4B ) and specific activity of NQO1 (Fig. 4C) significantly increased in the setting where KEAP1 expression was significantly reduced by 80% (p<0.01 siKEAP1 versus scrambled). Interestingly, no induction of GSTA1 transcripts was detected, suggesting that the SFN-mediated induction of this gene is Nrf2-independent. Also unexpectedly, levels of COMT transcripts as well as COMT protein were significantly decreased 60-70% by the siKEAP1 treatment (p<0.01 for COMT protein level in siKEAP1 versus scrambled) (Fig 4A & 4B) . Comparable results were seen using shKEAP1 knockdown (data not shown). COMT is not known to be a direct Nrf2 regulated gene and the mechanism underlying this response is not known.
Modulation of levels of depurinating estrogen-DNA adducts and estrogen metabolites by SFN or siKEAP1 treatment
At 48 hr after E 2 treatment, the summed levels of the depurinating adducts, 4- (Fig. 5A) . Although E 2 was added to the cells, there was with siKEAP1 treatment (Fig. 5E ), while levels of the 4-OHE 1/2 -glutathione conjugates were not significantly different (Fig. 5F ). Both outcomes are consistent with the effects of siKEAP1 on COMT and GSTA1 transcripts (Fig. 4A) . Similar results were seen following 4-OHE 2 treatment. 4-OHE 1/2 -1-N3Adenine and 4-OHE 1/2 -1-N7Guanine adducts declined 90% in siKEAP1 treated cells compared to scrambled vector (Fig. 5D) are not [29] [30] [31] . 4-OHE 2 and E 2 -3,4-quinone are mutagenic in mouse skin and rat mammary gland [9, 32] . The genotoxicity of 4-OHE 2 and E 2 -3,4-quinone was also demonstrated in the Big Blue rat embryonic cell line, but no mutations were observed after treatment of the cells with 2-OHE 2 [33] . The much greater carcinogenic activity of 4-OHE 1/2 compared to 2-OHE 1/2 likely reflects the far greater propensity of E 1/2 -3,4-quinones to form estrogen-DNA adducts compared to E 1/2 -2,3-quinones [7] . Transgenic mice with ERα knocked out (ERKO/wnt-1 mice) provide another model that demonstrates the critical role of estrogen genotoxicity in carcinogenesis. The wnt-1 transgene induced mammary tumors in female ERKO/wnt-1 mice, despite the lack of ERα. [34] . Mammary tumors developed in these mice even when ovariectomized mice were implanted with both E 2 and the anti-estrogen ICI-182,780 [35] suggesting that non-ER pathways such as metabolism to the genotoxic quinones that form the adenine and guanine adducts contribute to mammary tumor development.
MCF-10A cells are an immortalized mammary epithelial cell line lacking ERα.
Treatment of MCF-10A cells with E 2 or 4-OHE 2 generates the depurinating estrogen-DNA adducts and transformation of the cells, as detected by their ability to form colonies in soft agar [36] . This transformation can also occur in the presence of the antiestrogens, tamoxifen or ICI-182,780 [37] . Thus, DNA damage and cell transformation by estrogens do not require a functional ERα signaling pathway. Consequently, strategies to prevent the formation of estrogen-DNA adducts may alter the initiation and development of both ERα positive and negative cancers.
The depurinating estrogen-DNA adducts that efflux from cells and tissues are excreted in urine, allowing their identification and quantification as biomarkers of risk of developing breast cancer [7, [12] [13] [14] . High levels of estrogen-DNA adducts have been observed in analyses of urine and serum from women at high risk for or diagnosed with breast cancer compared to women at normal risk (12) (13) (14) . Levels of DNA adducts are strongly influenced by the balance of enzymes involved in their bioactivation to reactive intermediates and their detoxication. Protective enzymes such as COMT, GSTs, and NQO1 can decrease steady-state levels of E 1/2 -3-4-quinones and the resulting depurinating estrogen-DNA adducts in cell culture models (Fig. 1) . For example, inhibition of COMT led to an increase in oxidative DNA damage in human breast cancerderived MCF-7 cells, [38] and formation of E 1/2 -3-4-quinone adenine and guanine DNA adducts in MCF-10F cells [39] . Conjugation of the quinones with glutathione catalyzed by GSTs and reduction by NQO1 of the quinones back to catechol estrogens can be envisioned to mitigate the formation of depurinating adducts. A series of isogenic MCF-10F cells stably expressing polymorphic variants of NQO1 with lower capacity to reduce estrogen quinones compared to wild-type NQO1 consistently led to increased formation of estrogen-DNA adducts from E 2 -3,4-quinone (40) .
As seen in an earlier study using the phytochemical resveratrol in MCF-10F cells it is possible to reduce the formation of estrogen-DNA adducts and to decrease E 2 -induced transformation to anchorage-independent growth [4] . We show here that the broadly effective chemopreventive agent isolated from broccoli, SFN, also exerts strong protective effects against the DNA damaging actions of estrogens in the MCF-10A cells. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 SFN also reduces levels of CYP1B1 protein in these cells, which could dampen formation of the catechol estrogens. However, the protection by SFN is also seen when 4-OHE 2 is administered to cells, a metabolite that is a product of CYP1B1 action. Thus, it is unlikely that inhibition of estrogen bioactivation is critical to protection in this setting.
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